Peramivir Stumbles In Phase II Influenza Study; BioCryst Falls Sep. 21, 2007 By Jennifer Boggs Shares of BioCryst Pharmaceuticals Inc. tumbled more than 30 percent following a Phase II miss with the influenza drug peramivir, despite assurances from company executives that inadequate needle-lengths were to blame. (BioWorld Today) Read More
NewCo News: ImmunoBiosciences Using ICV Platform To Improve Vaccines Sep. 21, 2007 By Trista Morrison
International report: bioMérieux acquires Australian microbiology company BTF Sep. 20, 2007 By John Brosky
RSS